INOVIO Pharmaceuticals, Inc. (INO) announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at an exercise price of $1.75 per share.
The gross proceeds from the offering by INOVIO Pharmaceuticals, Inc. (INO) are expected to be approximately $25 million.
The offering is anticipated to close on or about July 7, 2025.
Piper Sandler & Co. (PIPR) is acting as the sole active book-running manager for the offering.
Oppenheimer & Co. Inc. is also serving as a passive bookrunner for the offering.
